NRAS mutations are present in 0–18% of CM patients and lead to the continuous activation of both MAPK and PI3 K signaling pathways; these mutations are generally mutually exclusive with BRAF mutations. This evidence concerns the gene NRAS and cutaneous mastocytosis.